Corporate Ambassador Spotlight
Novocure – A Global Oncology Company
Founded in 2000, Novocure is a global oncology company headquartered in Baar, Switzerland. The company’s mission is to extend survival in some of the most aggressive forms of cancer through the development and commercialization of its innovative therapy, Tumor Treating Fields.
Tumor Treating Fields (TTFields) are electric fields that exert physical forces to kill cancer cells via a variety of mechanisms. TTFields do not significantly affect healthy cells because they have different properties (including division rate, morphology and electrical properties) than cancer cells. These multiple, distinct mechanisms work together to target and kill cancer cells. Due to these multimechanistic actions, TTFields therapy can be added to cancer treatment modalities in approved indications, and in preclinical models, demonstrates enhanced effects across solid tumor types when used with chemotherapy, radiotherapy, immune checkpoint inhibition or targeted therapies. TTFields therapy provides clinical versatility that has the potential to help address treatment challenges across a range of solid tumors.
TTFields therapy is delivered to the tumor site continuously through a non-invasive, wearable medical device that has been FDA-approved to treat multiple solid tumor cancers. To date more than 40,000 patients have been treated with TTFields therapy around the world.
Novocure provides around-the-clock personalized assistance for patients using TTFields therapy through its “MyNovocure” support program.
With four ongoing clinical trials, one Phase II and three Phase III, and extensive pre-clinical research, Novocure is committed to advancing the science of TTFields. Ongoing research includes the use of TTFields with radiation therapy to expand the potential of TTFields therapy in some of the most difficult to treat cancers.
Novocure is a proud, longtime corporate ambassador to ASTRO. The company appreciates the strong partnership with ASTRO and radiation oncologists in education and advocacy, for the growth and stability of the radiation oncology community as well as education about TTFields. We look forward to continued collaboration to advance patient care through health policy, innovative treatment delivery and investment in research.
For more information, visit Novocure.com.
